These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39033284)

  • 1. Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems.
    Kumar S; Mohanty A; Mantry P; Schwartz RE; Haff M; Therapondos G; Noureddin M; Dieterich D; Girgrah N; Cohn K; Savanth M; Fuchs M
    BMC Prim Care; 2024 Jul; 25(1):265. PubMed ID: 39033284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
    Allen AM; Charlton M; Cusi K; Harrison SA; Kowdley KV; Noureddin M; Shubrook JH
    Postgrad Med; 2024 Apr; 136(3):229-245. PubMed ID: 38465573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
    Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
    Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIS2+
    Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
    J Hepatol; 2023 Dec; 79(6):1542-1556. PubMed ID: 37364790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
    Zeng J; Fan JG; Francque SM
    United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Muddle. MASLD and MASH on the Horizon.
    Meagher T
    J Insur Med; 2023 Jul; 50(2):147-149. PubMed ID: 38358924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ; ;
    J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Kanwal F; Neuschwander-Tetri BA; Loomba R; Rinella ME
    Hepatology; 2024 May; 79(5):1212-1219. PubMed ID: 38445559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
    Vacca M; Kamzolas I; Harder LM; Oakley F; Trautwein C; Hatting M; Ross T; Bernardo B; Oldenburger A; Hjuler ST; Ksiazek I; Lindén D; Schuppan D; Rodriguez-Cuenca S; Tonini MM; Castañeda TR; Kannt A; Rodrigues CMP; Cockell S; Govaere O; Daly AK; Allison M; Honnens de Lichtenberg K; Kim YO; Lindblom A; Oldham S; Andréasson AC; Schlerman F; Marioneaux J; Sanyal A; Afonso MB; Younes R; Amano Y; Friedman SL; Wang S; Bhattacharya D; Simon E; Paradis V; Burt A; Grypari IM; Davies S; Driessen A; Yashiro H; Pors S; Worm Andersen M; Feigh M; Yunis C; Bedossa P; Stewart M; Cater HL; Wells S; Schattenberg JM; Anstee QM; ; Tiniakos D; Perfield JW; Petsalaki E; Davidsen P; Vidal-Puig A
    Nat Metab; 2024 Jun; 6(6):1178-1196. PubMed ID: 38867022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
    Younossi ZM; Alqahtani SA; Alswat K; Yilmaz Y; Keklikkiran C; Funuyet-Salas J; Romero-Gómez M; Fan JG; Zheng MH; El-Kassas M; Castera L; Liu CJ; Wai-Sun Wong V; Zelber-Sagi S; Allen AM; Lam B; Treeprasertsuk S; Hameed S; Takahashi H; Kawaguchi T; Schattenberg JM; Duseja A; Newsome PN; Francque S; Spearman CW; Castellanos Fernández MI; Burra P; Roberts SK; Chan WK; Arrese M; Silva M; Rinella M; Singal AK; Gordon S; Fuchs M; Alkhouri N; Cusi K; Loomba R; Ranagan J; Eskridge W; Kautz A; Ong JP; Kugelmas M; Eguchi Y; Diago M; Yu ML; Gerber L; Fornaresio L; Nader F; Henry L; Racila A; Golabi P; Stepanova M; Carrieri P; Lazarus JV;
    J Hepatol; 2024 Mar; 80(3):419-430. PubMed ID: 37984709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.